RUNX1-RUNX1T1 is a suspected disease in the field of blood tumours, with clinical performance being complex and often involving multi-system congestion. Early identification and normalisation are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological biopsy.
The platform can assist in linking a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. 21) The treatment regimen for RUNX1-RUNX1T1 needs to be individualized, and typically includes multidimensional management, such as drug therapy, rehabilitation interventions, regular follow-up, and more. In recent years, with the development of treatment-oriented, immune-regulated therapy, and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of blood oncology to provide the following services to patients: 1. Remote pre-diagnosis: pre-examination of medical history, precise diagnostic directions and medical advice by a team of experts; 2. Interviews in China: arranging face-to-face diagnosis with authoritative experts, developing personalized treatment programs; 3.
Full-service: one-stop services: providing medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.